News
ACRS
6.41
+1.26%
0.08
Weekly Report: what happened at ACRS last week (0810-0814)?
Weekly Report · 4d ago
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Seeking Alpha · 08/10 12:49
Weekly Report: what happened at ACRS last week (0803-0807)?
Weekly Report · 08/10 09:06
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue
Simply Wall St · 08/07 22:27
Aclaris Therapeutics (ACRS) Gets a Buy from Piper Sandler
TipRanks · 08/07 15:27
Aclaris Q2 Net Loss Expands; Secures FDA's Fast Track Designation For Modzatinib In Lichen Planus
NASDAQ · 08/07 05:20
Aclaris Updates At-The-Market Equity Sales Agreement
TipRanks · 08/06 22:22
Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib
Dow Jones · 08/06 21:34
Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib
TipRanks · 08/06 21:30
Aclaris Therapeutics: Buy Rating Reiterated on Differentiated Pipeline and Extended Runway; $13 Price Target Maintained
TipRanks · 08/06 21:25
Aclaris Therapeutics files automatic mixed securities shelf
TipRanks · 08/06 21:10
Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate
Benzinga · 08/06 11:00
*Aclaris Therapeutics 2Q Rev $1.63M >ACRS
Dow Jones · 08/06 10:59
*Aclaris Therapeutics 2Q Loss/Shr 15c >ACRS
Dow Jones · 08/06 10:59
Press Release: Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Dow Jones · 08/06 10:59
*Aclaris Therapeutics 2Q Loss $21.5M >ACRS
Dow Jones · 08/06 10:59
Press Release: Aclaris Therapeutics Reports -2-
Dow Jones · 08/06 10:59
Biotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS
NASDAQ · 08/06 08:54
Weekly Report: what happened at ACRS last week (0727-0731)?
Weekly Report · 08/03 09:06
Weekly Report: what happened at ACRS last week (0720-0724)?
Weekly Report · 07/27 09:06
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).